Buscar
Moderna Inc
MRNAAñadir a la lista de seguimiento
66.910USD
+7.160+11.98%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
26.56BCap. mercado
PérdidaP/E TTM
Más Datos de Moderna Inc Compañía
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Información de Moderna Inc
Símbolo de cotizaciónMRNA
Nombre de la empresaModerna Inc
Fecha de salida a bolsaDec 07, 2018
Director ejecutivoBancel (Stephane)
Número de empleados5800
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 07
Dirección325 Binney Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Teléfono16177146500
Sitio Webhttps://www.modernatx.com/
Símbolo de cotizaciónMRNA
Fecha de salida a bolsaDec 07, 2018
Director ejecutivoBancel (Stephane)
Ejecutivos de Moderna Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.64M
+0.29%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
--
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
73.56K
+9.80%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
65.69K
+11.22%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
19.32K
+84.03%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
4.76K
+85.23%
Mr. Stephane Bancel
Mr. Stephane Bancel
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Noubar B. Afeyan, Ph.D.
Dr. Noubar B. Afeyan, Ph.D.
Non-Executive Independent Chairman of the Board, Co-Founder
Non-Executive Independent Chairman of the Board, Co-Founder
--
--
Dr. Francois Nader, M.D.
Dr. Francois Nader, M.D.
Independent Director
Independent Director
--
--
Ms. Tracey Franklin
Ms. Tracey Franklin
Chief People and Digital Technology Officer
Chief People and Digital Technology Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.64M
+0.29%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
--
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
73.56K
+9.80%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
65.69K
+11.22%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
19.32K
+84.03%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
4.76K
+85.23%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Moderna Inc?
Los cinco principales accionistas de Moderna Inc son: Dr. Stephen Hoge, M.D.
¿Cuántas instituciones poseen acciones de Moderna Inc (MRNA)?
A fecha de 2026Q1, 1886 instituciones poseen acciones de Moderna Inc, con un valor de mercado combinado de aproximadamente 313.06M, lo que representa el 78.90% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 10100814.00.
¿Cuál es la mayor fuente de ganancias de Moderna Inc?
El 2026Q1, el segmento empresarial COVID generó la ganancia más alta para Moderna Inc, ascendiendo a 1.81B y representando el 99.56% de la ganancia total.
